Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer-Reference-Cited by-同舟云学术

Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer

Published:2018-03-25 Issue:5 Volume:9 Page:613-620
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Zhai Xiaoyu¹,Hong Ruoxi²,Fan Ying¹,Yuan Peng¹,Wang Jiayu¹,Sang Die³,Chen Junlin⁴,Zhao Chunying⁴,Ou Kaiping³,Ma Fei¹,Xu Binghe¹^ORCID

Affiliation:

1. Department of Medical Oncology, National Cancer Center/Cancer Hospital; Chinese Academy of Medical Sciences and Peking Union Medical College; Beijing China

2. Department of Medical Oncology; Sun Yat-sen University Cancer Center; Guangzhou China

3. Department of Medical Oncology; Beijing Chaoyang District San Huan Cancer Hospital; Beijing China

4. Department of Medical Oncology; Cancer Hospital of HuanXing ChaoYang District Beijing; Beijing China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1759-7714.12627/fullpdf

Reference32 articles.

1. Chemotherapy for metastatic breast cancer;Mayer;Hematol Oncol Clin North Am,2007

2. Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experience;Ozkan;Neoplasma,2012

3. Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor;McLeskey;Am J Pathol,1998

4. Blockade of neoangiogenesis, a new and promising technique to control the growth of malignant tumors and their metastases;Grimm;Curr Vasc Pharmacol,2009

5. Vascular endothelial growth factor and bevacitumab in breast cancer;Bando;Breast Cancer,2007